Evidence map›Paper›PMID 37637057›Full record

ArticleFrontiers in oncology2023

Case Report: Response to

Yu Yang, Han Liu, Tao-Hua Liu, Xi-Run Zheng, Bin Wu, Dong-Jing Zhou, Guang-Juan Zheng, Xiao-Shu Chai

Open access · goldAbstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yu YangDepartment of Pathology, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
Han LiuDepartment of Pathology, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
Tao-Hua LiuDepartment of Pathology, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
Xi-Run ZhengDepartment of Pathology, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
Bin WuDepartment of Pathology, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
Dong-Jing ZhouDepartment of Image, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
Guang-Juan ZhengDepartment of Pathology, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
Xiao-Shu ChaiDepartment of Oncology, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
Guangzhou University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung adenosquamous carcinoma (ASC) is a rare heterogeneous tumor containing two distinct components of adenocarcinoma (ADC) and squamous cell carcinoma (SQCC). The limited biopsy sampling of the primary tumor might have overlooked either the ADC component or the SQCC component, resulting in a misdiagnosis of pure histology. Genotyping for driver mutations is now routinely performed in clinical settings to identify actionable oncogenic mutations and gene arrangements. Additionally, somatic mutations can potentially serve as a marker of clonal relationships. We report a rare case of ASC lung cancer, in which metastases were identified as ADC, while the primary was initially diagnosed as SQCC based on a fibrobronchoscope brush biopsy. The primary and metastatic tumors shared

Indexed as

adenosquamous carcinomaALK rearrangementhistomorphologymetastasis lung cancertargeted therapy

Identifiers

PMID37637057
PMCPMC10450948
OpenAlexW4385758932

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.